Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Q&A: 20-Hour 510(k)? Attorney Calls On Courts To Update Its Figures

This article was originally published in The Gray Sheet

Executive Summary

In an interview with "The Gray Sheet," medical device attorney Jeffrey Shapiro discusses his effort to get the federal courts to modify what he says is a drastically outdated perception of the 510(k) process.

You may also be interested in...



Unlocking Legalities: To Change How Courts View 510(k) Clearances, Industry Seeks 'Supreme' Support

Medtech's legal realm wants the US Supreme Court to correct the record on 510(k)s next term, and they say they've found the right case to make that happen: a J&J/Ethicon mesh device suit where the lower court refused to let the jury hear any mention at all of US FDA or the product's 510(k) clearance. Courts say 510(k)s lack sufficient relevance to support a company's case for product safety, but industry says that view is based on outdated facts and is fundamentally unfair.

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel